Dihexa

What it is

Dihexa (also called PNB-0408) is a synthetic six-carbon angiotensin IV analog with structural modifications that confer oral bioavailability and CNS penetration. It was developed at Washington State University by Joseph Harding and colleagues based on research into the cognitive effects of angiotensin IV signaling in the hippocampus and other brain regions.

The peptide has been promoted in some circles as an extremely potent cognitive enhancer based on preclinical research showing effects on synaptic connections in animal models. These claims have outpaced the available human evidence substantially.

Mechanism of action

Dihexa is proposed to act through:

• Hepatocyte growth factor (HGF) potentiation: Dihexa potentiates the binding of HGF to its receptor c-Met, which has documented effects on synaptic plasticity and dendritic complexity
• Synaptogenesis: animal studies show increases in dendritic spine density in hippocampal neurons
• Cognitive effects in animal models: improvements in spatial learning and memory tasks

Clinical evidence

Human clinical trial evidence on Dihexa is essentially absent. The compound has been characterized in preclinical studies but has not progressed to substantial human clinical research. Clinical use is based on extrapolation from animal data combined with mechanistic theory.

Why we don’t prescribe it at The Tide

The Tide does not prescribe peptides based primarily on preclinical animal data without supporting human clinical evidence. For cognitive support indications:

• We have established options (Semax, Cerebrolysin) with substantial clinical evidence in their countries of approval
• The fundamental approach of addressing sleep, exercise, stress, hormonal optimization, and other foundational factors typically produces more meaningful cognitive benefits than experimental peptides
• Specific cognitive concerns warrant appropriate medical evaluation rather than empiric peptide trials

Dihexa represents an interesting research compound that has not yet demonstrated readiness for clinical prescribing.

Side effects and contraindications

Human safety data is essentially absent. Theoretical concerns about HGF signaling in cancer contexts (HGF/c-Met signaling supports some malignancies). We avoid prescribing without adequate safety data.